Structure-activity relationships of constrained phenylethylamine ligands for the serotonin 5-HT2 receptors

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Isberg, Vignir ^a   Paine, James ^a   Leth Petersen, Sebastian ^a   Kristensen, Jesper L ^a   Gloriam, David E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PHENETHYLAMINE DERIVATIVE; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATION; CRYSTAL STRUCTURE; CYCLIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION;

CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; PHENETHYLAMINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892389858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078515     Document Type: Article

References (31)

1. Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Annual Review of Medicine 60: 3552366.
2. Ramage AG, Villalon CM (2008) 5-hydroxytryptamine and cardiovascular regulation. Trends in Pharmacological Sciences 29: 4722481.
3. Monti JM, Jantos H (2008) The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Progress in Brain Research 172: 6252646.
4. Gershon MD, Tack J (2007) The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 3972414.
5. Katzman MA (2009) Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 23: 1032120.
6. Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. Molecular Psychiatry 12: 9042922.
7. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007) Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. Drugs 67: 27255.
8. Goadsby PJ (2007) Serotonin receptor ligands: treatments of acute migraine and cluster headache. Handb Exp Pharmacol: 1292143.
9. Moltzen EK, Bang-Andersen B (2006) Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century - a medicinal chemistry survey. Curr Top Med Chem 6: 180121823.
10. Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology, biochemistry, and behavior 71: 5332554.
11. Roth BL (2011) Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation. Neuropharmacology 61: 3482354.
12. Gonzalez-Maeso J, Sealfon SC (2009) Psychedelics and schizophrenia. Trends in Neurosciences 32: 2252232.
13. Nichols DE (2004) Hallucinogens. Pharmacology & therapeutics 101: 1312181.
14. Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, et al. (1996) Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem 39: 295322961.
15. Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, et al. (1996) Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. Journal of Medicinal Chemistry 39: 295322961.
16. Whiteside MS, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE, Monte A (2002) Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorganic and Medicinal Chemistry 10: 330123306.
17. Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE (1998) A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. Journal of medicinal chemistry 41: 514825149.
18. Braden MR, Nichols DE (2007) Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Molecular pharmacology 72: 120021209.
19. Braden MR (2007) Towards a Biophysical Basis of Hallucinogen Action.
20. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, et al. (2006) 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. Journal of medicinal chemistry 49: 579425803.
21. Monte AP, Marona-Lewikcka D, Cozzi NV, Nelson DL, Nichols DE (1995) Conformationally restricted tetrahydro-1-benzoxepin analogs of hallucinogenic phenethylamines. Med Chem Res 5.
22. Bradsher CK, Reames DC (1978) A new anionic cyclization of the Parham type. Selective ring opening of epoxides. The Journal of Organic Chemistry 43: 380023802.
23. Selander H, Nilsson JLG (1972) Tritium Exchange in Specifically Labelled Hydroquinone, Dihydrobenzofuranol and Chromanol Derivatives. Acta Chem Scand 26: 243322440.
24. Wubbels GG, Brown TR, Babcock TA, Johnson KM (2008) The element effect and nucleophilicity in nucleophilic aromatic photosubstitution (SN2Ar*). Local atom effects as mechanistic probes of very fast reactions. J Org Chem 73: 192521934.
25. Wacker D, Wang C, Katritch V, Han GW, Huang XP, et al. (2013) Structural Features for Functional Selectivity at Serotonin Receptors. Science.
26. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, et al. (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477: 5492555.
27. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 2352242.
28. (2013) Maestro. 9.5 ed. New York, NY: Schrödinger LCC.
29. (2012) SiteMap. 2.6 ed. New York, NY: Schrödinger LCC.
30. (2012) Glide. 5.8 ed. New York, NY: Schrödinger LCC.
31. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE (2001) Enantiospecific synthesis and pharmacological evaluation of a series of superpotent, conformationally restricted 5-HT(2A/2C) receptor agonists. Journal of Medicinal Chemistry 44: 100321010.